Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease No … ← Balancing the risks of venous thromboembolism and bleeding in abdominal surgery: factors to consider in personalising thromboprophylaxis From evidence to care delivery: Opportunities and risks in health and science policy. A position paper of the Association of the Scientific Medical Societies in Germany (AWMF) →